The Influencing Factors of 12 Week Efficacy of Polyethylene Glycol Losenatide in Type 2 Diabetes Patients

Summary

The effect of polyethylene glycol Losenatide on body fat, insulin resistance, weight, blood sugar, blood lipid, stomach volume and other factors in patients with type 2 diabetes through 12 week follow-up, and explore the factors affecting the efficacy, so as to provide more evidence-based medical basis for drug treatment and benefit patients.

Timeline

Start

2022-06-01

Primary completion

2023-12-31

Completion

2025-12-31

Publications

• Gu R, Zhou Y, Kong X, Luo Y, Li H, Ma J. Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study. Diabetes Metab Syndr Obes. 2026 Jul 10;19:592044. doi: 10.2147/DMSO.S592044. eCollection 2026.
• Zhu L, Li H, Zhang Y, Tao S, Yan R, Luo Y, Shen Z, Li H, Kong X, Ma J. Efficacy of 12-week treatment with polyethylene glycol loxenatide in obesity or overweight patients with type 2 diabetes: a multicenter, prospective cohort study based on the flash glucose monitoring system. Front Endocrinol (Lausanne). 2026 May 19;17:1810786. doi: 10.3389/fendo.2026.1810786. eCollection 2026.

Drugs

Indications